Pipeline-In-A-Pill: Still A Winning Strategy?
Executive Summary
“Pipeline-in-a-pill” has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.
You may also be interested in...
Managing Lifecycles Amid Stifling Competition
Biopharma is entering a new period of intense competition from new sources, requiring a change in approach to portfolio strategy and lifecycle management.
Gilead Made Gains In Oncology, Though Virology Remains King
Pipeline-in-a-product approaches have become popular in biopharma, and Gilead has been making significant strides.
Biotech’s Cambrian Explosion
An increasing number of sophisticated tools are on offer to address new therapeutic challenges and remaining unmet needs.